SynthesisInflammopharmacology2026
Therapeutic potential of L-carnitine in coronary artery disease: a systematic review.
Synthesis in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary artery disease (CAD) persists as a major global health burden, contributing significantly to both morbidity and mortality rates worldwide, mostly attributable to atherosclerosis and oxidative stress. L-carnitine (LC), a natural derivative of amino acid, plays a critical role in mitochondrial fatty acid transport and has demonstrated potential antioxidant as well as anti-inflammatory effects.
aimThis review aims to provide an integrated synthesis that bridges mechanistic evidence (anti-inflammatory, antioxidant) with clinical outcomes (mortality, arrhythmias) for LC supplementation in CAD, while critically appraising inconsistencies across the literature (e.g., heart failure, reinfarction).
methodsA systematic literature search was conducted in PubMed and Google Scholar databases until July 2025. Studies, including animal studies, case reports, cross-sectional studies, observational studies, retrospective analysis, randomized controlled trials, systematic review and meta-analyses, that investigating the effects of L-carnitine on cardiac function, oxidative stress, inflammation, and mortality in CAD patients were included. Articles that were not within the scope of the study, non-English papers, and those without translations were excluded. A total of 21 studies were identified based on the inclusion criteria.
resultsAcross mechanistic endpoints, LC was associated with reductions in inflammatory markers, oxidative stress indices, and cardiac injury biomarkers, with several trials noting improvements in left-ventricular function and lipid profiles. Regarding clinical endpoints, meta-analyses showed reductions in the incidence of all-cause mortality, ventricular arrhythmia, and anginal episodes. In contrast, results were inconsistent regarding heart failure and myocardial reinfarction outcomes.
conclusionsL-carnitine supplementation may offer cardioprotective benefits in CAD patients; however, given the inconsistent results regarding certain clinical endpoints, further large-scale, long-term randomized trials are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.